Chronic heart failure with moderately low ejection fraction

Chronic heart failure (CHF) as one of the cardiovascular complications is among the most frequent causes of death and repeated hospitalizations of patients, representing a great burden on the health care system. Currently, the assessment of left ventricular (LV) ejection fraction (EF) is the cornerstone of classification of patients with CHF, the main criterion for diagnosis, phenotyping, prognosis and decision on the choice of pharmacotherapy strategy. Traditionally, patients with heart failure were divided according to a threshold value of PV greater than or <50%. In 2016, CHF was divided into three subgroups depending on LVEF: CHF with low LVEF (HFrEF; LVEF <40%), CHF with moderately low LVEF (HFmrEF 40-49%), and preserved LVEF (HFрEF≥50%). At the same time, to date, the data on HFmrEF are extremely limited and are represented by single publications in this area. Therefore, the research aimed at studying this category of patients is very promising. The aim of the review is to analyze the current data on CHF, in particular epidemiology, etiology, clinical characteristics and prognosis of patients.

1. Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Artemyeva E.G., Badin Yu.V., Bakulina E.V., et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14 (in Russ.). DOI: 10.18087/cardio.2021.4.n1628. EDN: WSZNFS.

2. Fomin I.V. Chronic heart failure in Russian Federation: what do we know and what to do.Russian journal of cardiology. 2016;21(8):7-13 (in Russ.). DOI:10.15829/1560-4 071-2016-8-7-13. EDN: WHURET.

3. Savarese G., Stolfo D., Sinagra G., Lund L.H. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19(2):100-116. DOI: 10.1038/s41569-021-00605-5.

4. Osipova O.A., Bukatov V.V. Features of the course of myocardial infarction with ST segment elevation in elderly and senile patients. Research Results in Biomedicine. 2020;6(3):402-417 (in Russ.). DOI: 10.18413/2658-6533-2020-6-3-0-10. EDN: OLVDRA.

5. Pribylova N.N., Osipova O.A., Konovalova L.V. Evaluation of neurohormonal systems in patients with chronic heart failure due to postinfarction cardiosclerosis. Kursk scientific and practical journal “Man and his health”. 2010;(1):44-48 (in Russ.). EDN: MBHQYJ.

6. Osipova O.A., Vlasenko M.A., Godlevskaya O.M., Suyazova S.B. Cytokines in the development and progression of chronic heart failure. Vestnik novykh meditsinskikh tekhnologii. 2012;19(2):322-327 (in Russ.). EDN: PBGKGB.

7. Osipova O.A., Gosteva E.V., Shepel R.N., Belousova O.N., Tsurikova L.V., Petrichko T.A. Study of the role of oxidative stress, antioxidant protection and immune inflammation markers in the pathogenesis of chronic heart failure by the middle range ejection fraction in elderly patients depending on gender. Journal of Critical Reviews. 2020;7(15):14-21.

8. Tereshchenko S.N., Galyavich A.S., Uskach T.M., Ageyev F.T., Arutyunov G.P., Begrambekova Yu.L., Belenkov Yu.N., Boytsov S.A., et al. Chronic heart failure. Clinical Guidelines 2020.Russian Journal of Cardiology. 2020;25(11):311-374. (in Russ.). DOI: 10.15829/1560-4071-2020-4083. EDN: LJGGQV.

9. Thorvaldsen T., Benson L., Dahlstrom U., Edner M., Lund L.H. Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012. Eur J Heart Fail. 2016;18:503-511. DOI: 10.1002/ejhf.496

10. Polunina E.A., Voronina L.P., Popov E.A., Belyakova I.S., Polunina O.S., Tarasochkina D.S. Prognostic algorithms for the progression of chronic heart failure depending on the clinical phenotype. Cardiovascular Therapy and Prevention. 2019;18(3):41-47 (in Russ.). DOI: 10.15829/1728-8800-2019-3-41-47. EDN: MGSNAC.

11. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S., Falk V., González-Juanatey J.R., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200. DOI: 10.1093/eurheartj/ehw128.

12. Savarese G., Stolfo D., Sinagra G., Lund L.H. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19(2):100-116. DOI: 10.1038/s41569-021-00605-5.

13. McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M., Burri H., Butler J., et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-3639. DOI: 10.1093/eurheartj/ehad195.

14. Ibrahim N.E., Song Y., Cannon C.P., Doros G., Russo P., Ponirakis A., Alexanian C., Januzzi J.L. Jr. Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry®. ESC Heart Fail. 2019;6(4):784-792. DOI: 10.1002/ehf2.12455.

15. Takei M., Kohsaka S., Shiraishi Y., Goda A., Nagatomo Y., Mizuno A., Suzino Y., Kohno T., et al. Heart Failure With Midrange Ejection Fraction in Patients Admitted for Acute Decompensation: A Report from the Japanese Multicenter Registry. J Card Fail. 2019;25(8):666-673. DOI: 10.1016/j.cardfail.2019.05.010.

16. Farré N., Lupon J., Roig E., Gonzalez-Costello J., Vila J., Perez S., de Antonio M., Solé-González E., et al. Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain). BMJ Open. 2017;7(12):e018719. DOI: 10.1136/bmjopen-2017-018719.

17. Fonarow G.C., Stough W.G., Abraham W.T., Albert N.M., Gheorghiade M., Greenberg B.H., O'Connor C.M., Sun J.L., et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):768-777. DOI: 10.1016/j.jacc.2007.04.064.

18. Bulashova O.V., Nasibullina A.A., Khazova E.V., Gazizyanova V.M., Oslopov V.N. Chronic heart failure with intermediate left ventricular ejection fraction: clinical features and prognosis. Kazan Medical Journal. 2021;102(3): 293-301 (in Russ.). DOI: 10.17816/KMJ2021-293. EDN: TOZQZE.

19. Löfman I., Szummer K., Dahlström U., Jernberg T., Lund L.H. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail. 2017;19(12):1606-1614. DOI: 10.1002/ejhf.821.

20. Chioncel O., Lainscak M., Seferovic P.M., Anker S.D., Crespo-Leiro M.G., Harjola V.P., Parissis J., Laroche C., et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574-1585. DOI: 10.1002/ejhf.813.

21. Rickenbacher P., Kaufmann B.A., Maeder M.T., Bernheim A., Goetschalckx K., Pfister O., Pfisterer M., Brunner-La Rocca H.P., et al. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail. 2017;19(12):1586-1596. DOI: 10.1002/ejhf.798.

22. Farmakis D., Simitsis P., Bistola V., Triposkiadis F., Ikonomidis I., Katsanos S., Bakosis G., Hatziagelaki E., et al. Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. Clin Res Cardiol. 2017;106(5):359-368. DOI: 10.1007/s00392-016-1063-0.

23. Lund L.H., Claggett B., Liu J., Lam C.S., Jhund P.S., Rosano G.M., Swedberg K., Yusuf S., et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018;20(8):1230-1239. DOI: 10.1002/ejhf.1149.

24. Pashchenko E.V., Chesnikova A.I., Terent’yev V.P., Kudinov V.I., Devet’yarova E.A. Structural and functional features of the left ventricle in patients with heart failure in ischemic heart disease and thyrotoxicosis. Kuban Scientific Medical Bulletin. 2018;25(4):68-74 (in Russ.). DOI: 10.25207/1608-6228-2018-25-4-68-74. EDN: HBTQHB.

25. Kuz’michkina M.A., Kuzheleva E.A., Garganeyeva A.A., Ryabov V.V., Teplyakov A.T. Chronic heart failure with intermediate left ventricular ejection fraction in patients in a cardiological hospital. Clinical medicine. 2018;96(8):724-728 (in Russ.). DOI: 10.18821/0023-2149-2018-96-8-724-728. EDN: CTSYRQ.

26. Kalogeropoulos A.P., Fonarow G.C., Georgiopoulou V., Burkman G., Siwamogsatham S., Patel A., Li S., Papadimitriou L., et al. Characteristics and Outcomes of Adult Outpatients With Heart Failure and Improved or Recovered Ejection Fraction. JAMA Cardiol. 2016;1(5):510-518. DOI: 10.1001/jamacardio.2016.1325.

27. Koh A.S., Tay W.T., Teng T.H.K., Vedin O., Benson L., Dahlstrom U., Savarese G., Lam C.S.P., et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19(12):1624-1634. DOI: 10.1002/ejhf.945.

28. Sartipy U., Dahlstrom U., Fu M., Lund L.H. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail. 2017;5:565-574. DOI: 10.1016/j.jchf.2017.05.001

29. Zhirov I.V., Safronova N.V., Osmolovskaya Yu.F., Tereshchenko S.N. Prognostic value of atrial fibrillation in patients with heart failure with different left ventricular ejection fraction: results of the multicenter register RIF-CHF Russian Journal of Cardiology. 2021;26(1):44-57 (in Russ.). DOI: 10.15829/1560-4071-2021-4200. EDN: LWKKHY.

30. Shilyaeva N.V. Cardiorenal relationships in patients with chronic heart failure of ischemic etiology. Siberian Medical Review. 2017;4(106);30-35 (in Russ.). DOI: 10.20333/2500136-2017-4-30-35. EDN: ZVRMCR.

31. Karanadze N.A., Begrambekova Yu.L., Borisov E.N., Orlova Ya.A. The width of the distribution of erythrocytes as a predictor of low exercise tolerance in patients with chronic heart failure. Kardiologiya. 2022;62(4):30-35 (in Russ.). DOI: 10.18087/cardio.2022.4.n1813. EDN: TDFLJY.

32. Streng K.W., Nauta J.F., Hillege H.L., Anker S.D., Cleland J.G., Dickstein K., Filippatos G., Lang C.C., et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction.Int J Cardiol. 2018;271:132-139. DOI: 10.1016/j.ijcard.2018.04.001.

33. Savji N., Meijers W.C., Bartz T.M., Bhambhani V., Cushman M., Nayor M., Kizer J.R., Sarma A., et al. The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. JACC Heart Fail. 2018;6(8):701-709. DOI: 10.1016/j.jchf.2018.05.018.

34. Derevyanchenko M.V., Fabritskaya S.V., Ryndina Yu.A., Statsenko M.E. Renal and endothelial function in patients with chronic heart failure and obesity. European Journal of Case Reports in Internal Medicine. 2022;9(S1):13. DOI: 10.12890/2022_V9Sup1

35. Tsygankova O.V., Veretyuk V.V. Phenotypic clusters of patients with chronic heart failure with preserved and intermediate ejection fraction: new data and prospects.Russian Journal of Cardiology. 2021;26(4):81-92 (in Russ.). DOI: 10.15829/1560-4071-2021-4436. EDN: KWGLVJ.